A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

PURPOSE: Abiraterone acetate is used at a fixed oral dose of 1000 mg once daily (OD) taken fasted. By administering abiraterone acetate with food, a reduced dose can potentially be given while maintaining equivalent abiraterone exposure. Moreover, administering abiraterone acetate with a breakfast i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Lubberman, Floor J. E., Benoist, Guillemette E., Gerritsen, Winald, Burger, David M., Mehra, Niven, Hamberg, Paul, van Oort, Inge, van Erp, Nielka P.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820614/
https://ncbi.nlm.nih.gov/pubmed/31515667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03952-w
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires